Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2a Study of Anti-PD-L1 Monoclonal Antibody Durvalumab in Combination With Pralatrexate and Romidepsin, Oral 5-Aza and Romidepsin, Romidepsin Alone, or Oral 5-Azacitidine for Treatment of Patients With Relapsed and Refractory PTCL

Next Previous
X
Search
Trial Profile

Phase 1/2a Study of Anti-PD-L1 Monoclonal Antibody Durvalumab in Combination With Pralatrexate and Romidepsin, Oral 5-Aza and Romidepsin, Romidepsin Alone, or Oral 5-Azacitidine for Treatment of Patients With Relapsed and Refractory PTCL

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Mar 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Durvalumab (Primary) ; Pralatrexate (Primary) ; Romidepsin (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Adverse reactions

    • Most Recent Events

    • 16 Mar 2022 Planned End Date changed from 1 Feb 2021 to 1 Feb 2023.
    • 16 Mar 2022 Planned primary completion date changed from 1 Feb 2021 to 1 Feb 2023.
    • 08 Oct 2020 According to a Food and Drug Administration media release, the FDA has awarded research grant of $3.2 million over four years to the principal investigator Owen O'Connor, University of Virginia (Charlottesville, Virginia) to conduct this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top